Get the Stockscreener App
21.05
2.93%
0.60
After Hours:
21.24
0.19
+0.90%
Travere Therapeutics Inc stock is traded at $21.05, with a volume of 1.04M.
It is up +2.93% in the last 24 hours and up +21.54% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$20.45
Open:
$20.55
24h Volume:
1.04M
Relative Volume:
0.84
Market Cap:
$1.83B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-4.6264
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
+1.15%
1M Performance:
+21.54%
6M Performance:
+121.58%
1Y Performance:
+133.63%
1-Day Range:
$20.49
$21.23
1-Week Range:
$19.77
$21.56
52-Week Range:
$5.12
$21.56
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.05 | 1.83B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.3%What's Next? - MarketBeat
(TVTX) Technical Data - Stock Traders Daily
Wedbush Boosts Earnings Estimates for Travere Therapeutics - Defense World
What is Wedbush’s Estimate for TVTX FY2028 Earnings? - Defense World
Travere therapeutics CFO sells shares worth $16,383 - MSN
Travere therapeutics SVP William Rote sells $47,424 in stock - MSN
TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN
Travere therapeutics exec Elizabeth Reed sells common stock for $47,424 - MSN
Travere therapeutics chief commercial officer sells $30,002 in stock - MSN
Travere therapeutics director Roy Baynes sells $320,000 in stock - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline Sells 865 Shares - MarketBeat
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells 16,000 Shares of Stock - MarketBeat
Sandra Calvin Sells 925 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Eric M. Dube Sells 10,736 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $30,000.96 in Stock - MarketBeat
Travere therapeutics CEO Eric Dube sells shares for $208,922 - MSN
Travere Therapeutics (NASDAQ:TVTX) Sets New 1-Year HighWhat's Next? - MarketBeat
What is Wedbush's Estimate for TVTX FY2028 Earnings? - MarketBeat
TVTX Stock Soars to 52-Week High, Reaching $20.36 By Investing.com - Investing.com Australia
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock By Investing.com - Investing.com Canada
Travere therapeutics CFO sells shares worth $16,383 By Investing.com - Investing.com South Africa
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - Investing.com
Travere therapeutics CEO Eric Dube sells shares for $208,922 By Investing.com - Investing.com South Africa
Travere therapeutics director Roy Baynes sells $320,000 in stock By Investing.com - Investing.com Canada
Travere therapeutics chief commercial officer sells $30,002 in stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Predicts TVTX FY2025 Earnings - Defense World
FY2024 Earnings Estimate for TVTX Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Estimate for TVTX FY2024 Earnings? - MarketBeat
Analysts Issue Forecasts for TVTX FY2025 Earnings - MarketBeat
What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings? - Defense World
FY2026 Earnings Estimate for TVTX Issued By Leerink Partnrs - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World
Research Analysts Issue Forecasts for TVTX FY2024 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for TVTX Earnings - MarketBeat
What is HC Wainwright’s Estimate for TVTX FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for TVTX Issued By HC Wainwright - MarketBeat
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Alport Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2%Here's Why - MarketBeat
Travere Therapeutics Provides Corporate Update and 2025 Outlook - The Manila Times
Travere's FILSPARI Drives $50M Q4 Sales, European Expansion Gains Momentum with Multi-Country Launch - StockTitan
Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated at Cantor Fitzgerald - Defense World
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade - MSN
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):